Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychopharmacology (Berl). 2005 Apr;179(1):310-5. Epub 2004 Sep 30.

Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.

Author information

  • 1Department of Psychiatry and Psychotherapy, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. kellner@uke.uni-hamburg.de

Abstract

RATIONALE:

Preclinical findings have repeatedly shown an anxiolytic-like action of agonists at metabotropic glutamate receptors type II, such as LY354740.

OBJECTIVE:

We aimed to investigate the effect of LY544344, the prodrug of LY354740, upon experimental panic anxiety in humans.

METHODS:

Twelve healthy human volunteers were treated orally with 80 mg bid LY544344 for 1 week in a randomized placebo-controlled cross-over study before 50 mug cholecystokinin tetrapeptide (CCK-4) was injected intravenously. We assessed CCK-induced panic and anxiety symptoms and measured stress hormone release.

RESULTS:

While no significant treatment effect emerged in the entire sample, a significant reduction of the number of CCK-4-induced panic symptoms and of CCK-4-induced subjective anxiety ratings was detected after removing two subjects who did not show decreased CCK-4-elicited adrenocorticotropin (ACTH) release after LY544344 compared to placebo treatment.

CONCLUSIONS:

Further studies are needed to clarify the potential of LY544344 as a new anxiolytic or antipanic drug.

PMID:
15821951
DOI:
10.1007/s00213-004-2025-1
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center